Information Provided By:
Fly News Breaks for November 13, 2019
TTOO
Nov 13, 2019 | 07:35 EDT
Canaccord analyst Mark Massaro said the recent selloff in T2 Biosystems shares appears to be overdone. He noted the company delivered and inline quarter despite being having had ransom cyber-attack which lasted for several weeks and required the company to work in overdrive and perform manual operations for their business while seeking a remedy. He thinks the selloff is an over-reaction but Massaro lowered his price target to $3.00 from $3.50 on T2 Biosystems shares.
News For TTOO From the Last 2 Days
TTOO
Mar 28, 2024 | 09:08 EDT
T2 Biosystems announced that its multi-year capital equipment supplier agreement with Vizient has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood. "We are pleased to extend our multi-year agreement with Vizient, the nation's largest group purchasing organization. This reiterates the continued value that our products offer to patients suspected of sepsis," stated John Sperzel, Chairman and CEO of T2 Biosystems. "We believe there is a strong need for hospitals to have more effective rapid diagnostics that enable faster targeted therapy and this contract with Vizient improves hospitals' access to our life-saving technology."